Autopsy report · NCT02758132

Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases

“Low accruals”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month after it had already started.
• Ran for about 6 months before it stopped.
• 1 participant enrolled.
• Results were posted on the registry 3 years 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of Hawaii

Sponsor type

University, hospital or other

Conditions

Prostate Cancer

Interventions

Denosumab; Enzalutamide; Abiraterone; Prednisone

Participants

1

Sites

1

Countries

United States

Trials that died the same way

• Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy
  “low accrual” (97% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.